Skip to content
Open access

Bi-compartmental CSF-serum analysis of NfL and GFAP differentiates central and peripheral pathology in neuroinfectious diseases: A monocentric real-world cohort study.

Aug 2026 · Neurobiology of Disease · Vol 228, pp. 107565 · 0 citations · 41 references
Medicine

TL;DR

Bi-compartmental analysis revealed simultaneous elevation of CSF and serum NfL in TI+, indicating predominantly central origin, whereas PND demonstrated a shift toward higher sNfL levels suggesting peripheral origin.

Abstract

Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), established biomarkers of neuroaxonal injury and astroglial pathology, are frequently only assessed in blood, which limits conclusions regarding their origin. Bi-compartmental analyses of CSF and serum may help differentiate central or peripheral origin of biomarker elevation. Moreover, studies on NfL and GFAP in distinct neuroinfectious disease (NID) phenotypes, particularly those based on real-world cohorts, are limited. This retrospective monocentric study analyzed CSF and serum from patients with (meningo-)encephalitis/myelitis (TI+; n = 48), meningitis (TI-; n = 80), (cranial) nerve palsies/polyradiculitis (PND; n = 61), and 113 non-neuroinflammatory/non-neurodegenerative controls. A bi-compartmental model using scatter plots and simple linear regression was applied to assess the origin of blood biomarker levels and discriminate between central and peripheral pathology. CSF and serum NfL and GFAP z-scores were significantly higher in TI+ compared with TI- (CSF-GFAP p < 0.001/sGFAP p = 0.0083; CSF-NfL p = 0.003/sNfL p = 0.0004). TI+ and PND differed only in GFAP levels, which were higher in TI+ (CSF-GFAP p = 0.0049/sGFAP p = 0.003). The overall group effect (p ≤ 0.003) and principal findings remained significant after adjustment for age, sex, QAlb, and time since (symptom) onset to LP. Bi-compartmental analysis revealed simultaneous elevation of CSF and serum NfL in TI+, indicating predominantly central origin, whereas PND demonstrated a shift toward higher sNfL levels suggesting peripheral origin. Higher clinical severity (modified Rankin Scale 3-5) was associated with elevated serum and CSF GFAP and NfL (sGFAP p = 0.012/sNfL p = 0.002; CSF-GFAP p < 0.0001/CSF-NfL p = 0.0001), which also predicted unfavorable outcome at discharge (sGFAP p = 0.006/sNfL p = 0.004; CSF-GFAP p = 0.003/CSF-NfL p = 0.012). NfL and GFAP were associated with brain/myelon involvement in NID, predominantly reflecting central pathology. Despite strong CSF-serum correlations, bi-compartmental approaches provide additional insight into biomarker origin and disease compartment.

Read PDF

Similar papers

Oct 2026

B-225 Plasma GFAP and NfL as biomarkers of disease classification and differential diagnosis in optic neuritis

To test the hypothesis that plasma levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), which are an intermediate astrocyte and neuron filaments, respectively, are clinically useful biomarkers of disease classification and differential diagnosis in optic neuritis. Levels of...

Yu-Ting Xue, Xiang-Yi Liu · 0 citations
Oct 2026

B-057 From Plasma to Whole Blood: Validation of GFAP and NFL as Accessible Biomarkers in Stroke

Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light Chain (NfL) are critical blood-based biomarkers for the diagnosis and monitoring of a wide range of central nervous system (CNS) injuries. Current plasma-based assays require centrifugation, which prolongs turnaround time (TAT) and limits utility in e...

Yu-Ting Xue, Xiang-Yi Liu, Jia-Jing Wu · 0 citations
Oct 2026

Comparative diagnostic utility of cerebrospinal fluid biomarkers in multiple sclerosis.

BACKGROUND Multiple sclerosis (MS) diagnosis depends on clinical and magnetic resonance imaging (MRI) data; the need for confirmatory cerebrospinal fluid (CSF) biomarkers for differential diagnosis is a crucial step. OBJECTIVE We aim to investigate and compare the diagnostic value of CSF markers (e.g., chitinase 3-li...

Basant Rashad, Sohair K. Sayed, Tarek A. Rageh et al. · 0 citations
Open access Aug 2026

Neuroinflammatory Cerebrospinal Fluid Biomarkers as Predictors of Disease Progression in Multiple Sclerosis: Evidence from the Netherlands

Background: |Cerebrospinal fluid (CSF) contains neuroinflammatory biomarkers, which are molecules measured in central nervous system fluid to track immune activation (neuroinflammation) and glial response. The most significant forms of such markers are STREM tool microgel activity, YKL-40 estradiol activation, and GFAP...

B. J. Asten, A. M. Gelder, I. N. Creemers et al. · 0 citations
Open access Aug 2026

Serum neurofilament light chain as a biomarker of inflammatory activity in relapsing-remitting multiple sclerosis: a real-world longitudinal cohort study

Abstract Objectives Serum neurofilament light chain (sNfL) reflects neuroaxonal injury in relapsing-remitting multiple sclerosis (RRMS), but its clinical utility is limited by high interindividual variability and confounders such as renal function. Population-based thresholds may therefore be suboptimal for longitudina...

S. de las Heras Flórez, Gema García de la Rosa, Vicente Martín García et al. · 1 citation
Open access Oct 2026

Early neuro biomarker changes and electrophysiological nerve dysfunction in Swedish V50M hereditary transthyretin amyloidosis: a pilot study

This exploratory pilot study aimed to evaluate serum levels of neurofilament light chain (NfL), peripherin (PRPH), and glial fibrillary acidic protein (GFAP), and to explore their potential associations with nerve conduction studies (NCS) and nerve ultrasound (NUS) in a Swedish cohort of newly diagnosed patients wi...

S. Arvidsson, I. Anan, M. Olsson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.